Please assess the completion status of the following clinical trial:

Trial Title: Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of essential thrombocythaemia with high-risk profile.~Exclusion Criteria:~* previous treatment with cytoreductive drugs or Anagrelide~* pregnant women or women in childbearing age with inadequate contraception~* patients with contraindications for study drugs due to anaphylactoid reactions to either active or non-active ingredients~* known lactose intolerance~* cardiovascular diseases grade III-IV (Toxicity Criteria of the South West Oncology Group, 1992) - with a negative benefit/risk ratio~* severe renal disease (Creatinin Clearance \< 30 ml/min)~* severe liver disease (AST or ALT \> 5-times normal)~* coexisting, malignant, systemic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Anagrelide (Type: EXPERIMENTAL): None
- Hydroxyurea (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).